These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19220425)

  • 41. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?
    Cathérine D; Annelien P; Anne S; Luc A; Liesbeth VH; Gerlo S; Guy L
    Mult Scler Relat Disord; 2020 Jun; 41():102020. PubMed ID: 32146430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study.
    Arru G; Leoni S; Pugliatti M; Mei A; Serra C; Delogu LG; Manetti R; Dolei A; Sotgiu S; Mameli G
    Mult Scler; 2014 Feb; 20(2):174-82. PubMed ID: 23877972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
    Kerbrat A; Le Page E; Leray E; Anani T; Coustans M; Desormeaux C; Guiziou C; Kassiotis P; Lallement F; Laplaud D; Diraison P; Rouhart F; Sartori E; Wardi R; Wiertlewski S; Edan G
    J Neurol Sci; 2011 Sep; 308(1-2):98-102. PubMed ID: 21665227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.
    Rodi M; Dimisianos N; de Lastic AL; Sakellaraki P; Deraos G; Matsoukas J; Papathanasopoulos P; Mouzaki A
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571060
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta.
    Ozenci V; Kouwenhoven M; Teleshova N; Pashenkov M; Fredrikson S; Link H
    J Neuroimmunol; 2000 Aug; 108(1-2):236-43. PubMed ID: 10900359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.
    Putzki N; Kollia K; Woods S; Igwe E; Diener HC; Limmroth V
    Eur J Neurol; 2009 Mar; 16(3):424-6. PubMed ID: 19187261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
    Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E
    Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
    Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
    Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
    Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
    Oliver B; Fernández O; Orpez T; Alvarenga MP; Pinto-Medel MJ; Guerrero M; León A; López-Madrona JC; Maldonado-Sánchez R; García-León JA; Luque G; Fernández V; Leyva L
    Mult Scler; 2011 Mar; 17(3):368-71. PubMed ID: 21177326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action.
    Balasa RI; Simu M; Voidazan S; Barcutean LI; Bajko Z; Hutanu A; Simu I; Maier S
    CNS Neurol Disord Drug Targets; 2017; 16(9):1018-1026. PubMed ID: 28782487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of inflammatory genes in the colon of ulcerative colitis patients varies with activity both at the mRNA and protein level.
    Verma R; Verma N; Paul J
    Eur Cytokine Netw; 2013; 24(3):130-8. PubMed ID: 24197332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis.
    Caggiula M; Batocchi AP; Frisullo G; Angelucci F; Patanella AK; Sancricca C; Nociti V; Tonali PA; Mirabella M
    Scand J Immunol; 2005 Aug; 62(2):176-82. PubMed ID: 16101825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HepG2 human hepatoma cells express multiple cytokine genes.
    Stonāns I; Stonāne E; Russwurm S; Deigner HP; Böhm KJ; Wiederhold M; Jäger L; Reinhart K
    Cytokine; 1999 Feb; 11(2):151-6. PubMed ID: 10089137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production.
    Gonzalez H; Khademi M; Andersson M; Piehl F; Wallström E; Borg K; Olsson T
    J Neuroimmunol; 2004 May; 150(1-2):139-44. PubMed ID: 15081258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
    Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.